Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADT Inc (ADT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ADT Inc vs Inovio Pharmaceuticals Inc — how do they compare? ADT Inc trades at $7.31 (market cap $5.44B), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: ADT Inc is far larger — about 69.3× Inovio Pharmaceuticals Inc's market cap, and ADT Inc pays a 2.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

ADTINO
Market Cap
$5.44B$78.55M
Sector
IndustrialsHealth
52-Week High
$8.85$2.87
52-Week Low
$6.30$0.66
Enterprise Value
$13.13B$49.56M
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADT Inc

ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.

Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADT Inc

ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.

Read more on ADT

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO